OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
February 13, 2018
Unlike current approaches where bioconjugation is typically done following the manufacture of the monoclonal antibody and the cytotoxic drug, the new method begins with the antibody supernatants and eliminates the need for extensive chromatographic purification.
A $800-million acquisition of MPI Research expands Charles River's offerings for early-stage contract research.
February 09, 2018
The companies will partner to further immuno-oncology research using humanized mice.
February 02, 2018
Layout and supply details must be considered when implementing a fully disposable biopharmaceutical manufacturing process.
Hospitals form not-for-profit drug company to combat drug shortages and high prices.
Mark Egerton, PhD, chief executive officer of Quotient Sciences, shares insights on a new approach to accelerate drug development, which integrates formulation development, real-time adaptive GMP manufacturing, and clinical research within a single platform.
Industry lessons from a fast-track technology transfer of a soft-gelatin capsule (softgel) are multifold. This case study reviews the success factors for effective execution of the technology transfer, which include: strong relationship between the customer, the contract development and manufacturing organization, and other partners based on deep knowledge in the technology; established and proven quality-by-design processes; risk mitigation management; project leadership; flawless execution; and mutual trust.
February 01, 2018
Cambrex invests in development and laboratory facilities and adds staff.
Avista Pharma's strengthens early phase drug development offerings with acquisition of Solid Form Solutions.
Biopharm industry veteran Ralf Otto named to lead development and manufacturing at Rentschler Biopharma.